Alglucosidase alfa is indicated for:
Irrespective of gender only Infants (40 days - 1 year old) , Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)
Alglucosidase alfa is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid α-glucosidase deficiency). It is indicated in adults and paediatric patients of all ages.
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Alglucosidase alfa is contraindicated in the following cases:
No gender/age discrimination
Alglucosidase alfa may be excreted in breast milk. Because there are no data available on effects in neonates exposed to alglucosidase alfa via breast milk, it is recommended to stop breast-feeding when alglucosidase is used.
No gender/age discrimination
There are no data from the use of alglucosidase alfa in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown. Alglucosidase alfa should not be used during pregnancy unless clearly necessary.